SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : InterMune (nasdaq)ITMN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Young who wrote (351)1/25/2003 4:17:09 PM
From: IRWIN JAMES FRANKEL   of 508
 
Hi Mike,

"The actimmune extension data suggest the drug provides minimal, at best, help against IPF."

Data from the extension was uniformly negative (as best I can tell). The case for using Actimmune in IPF was weakened statistically by this additional data. But it does not follow that, "...the drug provides minimal, at best, help against IPF". If we were left to the extension data ALONE we would conclude not that the drug provided minimal help but rather that it was worse than placebo - it was NO HELP at all.

However, we have the data from the 48 weeks plus the extension period. When both are viewed together there is a 49% mortality improvement in the mild to moderate subset with a P=.02. That would be good enough for me if I were treating someone with mild to moderate IPF.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News